← Back to Portfolio

Sierra Oncology

Sierra Oncology is a late-stage drug development company based in Vancouver focused on the development and commercialization of Momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis including potential benefit to patients with anaemia. The product is in a Phase III clinical study in second line myelofibrosis patients and to date has over 820 patients of clinical data with some patients on drug for over 8 years.

Sierra is listed on the Nasdaq with ticker: SRRA

LocationVancouver, Canada
CEOStephen Dilly
Partner Andrew Sinclair